Acquisitions boost revenues at Dechra

INTERNATIONAL veterinary products company Dechra Pharmaceuticals has enjoyed strong full-year trading with a 22% increase in turnover, boosted by the acquisitions it made through the year.

The listed Northwich company said underlying operating profit came in at £52.9m (2015: £44.4m), on revenue of £247.6m (2015: £203.5m) for the year to the end of June. Pre-tax profits stood at £14.5m.

Dechra said it continues to outperform in the majority of therapeutic areas and markets in which it trades, especially in the US, while its product development pipeline has delivered two novel global products and several regional and national registrations in the period.

The three acquisitions it made during the year, provided the firm with critical mass and an enhanced product development pipeline in the US market, poultry vaccine development capabilities to broaden its EU food producing animal products business, and a marketing and registration platform for Dechra’s portfolio in Mexico.

Ian Page, chief executive, said: “With three acquisitions, pipeline product launches, successful trading in our new subsidiaries and solid growth in our focus portfolio, Dechra has delivered another strong performance in the 2016 financial year.”